301 results
Page 7 of 16
8-K
EX-99.1
dp3k1 fxppq7h6e5
8 Aug 19
Trovagene Announces Second Quarter 2019 Results and Highlights
4:53pm
8-K
EX-99.1
nzfz2r
22 Jul 19
ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation
11:55am
8-K
EX-99.2
vf6pn6byxz
15 Jul 19
Regulation FD Disclosure
12:03pm
8-K
EX-99.1
rfeyl6jtjw577
15 Jul 19
Regulation FD Disclosure
12:03pm
8-K
EX-99.1
at0i7jrf1y1j lc
9 Jul 19
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
11:20am
8-K
EX-99.1
aei bzxalm
7 Jun 19
Trovagene Company Update
4:06pm
8-K
EX-99.1
na02 erd9
31 May 19
Other Events
9:09am
8-K
EX-99.1
t8twq7amhmee77hd58zl
23 May 19
Other Events
9:25am
POS AM
zjks0oj15oto4prt
21 May 19
Prospectus update (post-effective amendment)
9:11am
8-K
EX-99.1
149s918 em
13 May 19
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price
3:47pm
8-K
EX-10.1
sve5o mlkm8ke9
13 May 19
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price
3:47pm
POS AM
04ljv4z
10 May 19
Prospectus update (post-effective amendment)
4:57pm
8-K
EX-99.1
zdpp3s
8 May 19
Trovagene Announces First Quarter 2019 Results and Highlights
12:00am
POS AM
d2omk38jrzt8ym
25 Apr 19
Prospectus update (post-effective amendment)
12:00am
8-K
EX-99.1
99wsc4xg7wuzcl
23 Apr 19
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
2:39pm
8-K
EX-99.2
lfmcafu
5 Apr 19
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
10:03am
8-K
EX-10.1
4ao rwkh7
5 Apr 19
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
10:03am
8-K
EX-99.1
6txbr lpz
5 Apr 19
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
10:03am